Sugi Predict

Sugi Predict / Compounds / SCHEMBL4032310

SCHEMBL4032310

SCHEMBL4032310

CCOC(=O)c1ncc(Br)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ KDM4E B2RXH2 4/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030683 0.83 KMT2A (0.41) PKMKMT2ACYP1A2KDM4ENPC1
SCHEMBL23693030 0.83 ALDH1A1 (0.42) MAPTKMT2AKDM4ENPC1RAB9A
SCHEMBL23214097 0.82 ALDH1A1 (0.38) PKMGAAMAPTKMT2AIDO1
SCHEMBL22405756 0.81 KDM4E (0.37) GAAKMT2ACYP1A2KDM4ENPC1
SCHEMBL22424328 0.80 KDM4E (0.44) GAAMAPTKMT2ACYP1A2KDM4E
SCHEMBL13813433 0.79 POLB (0.39) PKMGAAMAPTKMT2ACYP1A2
Hydrochloric Acid SCHEMBL7170504 0.79 KDM4E (0.43) GAAMAPTKMT2ACYP1A2KDM4E
SCHEMBL13130413 0.78 CYP1A2 (0.43) GAAMAPTKMT2ACYP1A2KDM4E
SCHEMBL29957431 0.78 TSHR (0.40) PKMMAPTKMT2ACYP1A2KDM4E
SCHEMBL4034443 0.76 GABRA1 (0.39) PKMMAPTKMT2ACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-20260035358-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2026-02-05 — — US disclosed
US-12421211-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2025-09-23 — — US disclosed
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-05 — — US disclosed
EP-4482583-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-01-01 — — EP disclosed
US-20240368117-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
EP-4211116-B1 NOVEL HETEROCYCLIC ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2024-08-07 — — EP disclosed
CN-118119609-A Imidazole derivatives and their use as antibiotics 豪夫迈·罗氏有限公司 2024-05-31 — — CN disclosed
EP-4370514-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS F. Hoffmann-La Roche AG (CH) 2024-05-22 — — EP disclosed
WO-2024069448-A1 SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-04-04 — — WO disclosed
EP-1887003-A1 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES Boehringer Ingelheim Pharmaceuticals, Inc. (US) 2008-02-13 — — EP disclosed
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds COGAN DEREK 2007-06-21 — — US disclosed
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds COGAN DEREK 2007-06-21 — — US disclosed
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds COGAN DEREK 2007-06-21 — — US disclosed
US-7214802-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-05-08 — — US disclosed
US-7214802-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-05-08 — — US disclosed
US-7214802-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-05-08 — — US disclosed
EP-1725544-A1 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-11-29 — — EP disclosed
US-20060079519-A1 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-04-13 — — US disclosed
WO-2005090333-A1 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421211-B2 Heterocyclic compounds F12, C1R, MRPL21 PKM 2025/4885GAA 1425/4885MAPT 4201/4885
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS MRPL21, WIZ, CFTR PKM 910/4885GAA 1534/4885MAPT 3615/4885
US-20070142371-A1 Anti-Cytokine Heterocyclic Compounds TNF, IL6, IL1A PKM 3386/4885GAA 476/4885MAPT 3851/4885
US-20260035358-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF CRBN, WEE1, WEE2 PKM 1179/4885GAA 3900/4885MAPT 643/4885
US-20060079519-A1 Anti-cytokine heterocyclic compounds TNF, IL6, IL1A PKM 3386/4885GAA 476/4885MAPT 3851/4885
US-20240368117-A1 HETEROCYCLIC COMPOUNDS F12, C1R, MRPL21 PKM 2025/4885GAA 1425/4885MAPT 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.